SCYX.US Scynexis Inc

Healthcare Pharmaceuticals USA Stocks
2.90 USD
Close of Nov 17, 2026
2.70 9.12
Market cap
USD 28.9M
P/E
-
P/B
0.54x
ROE
-50.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SCYX.US undervalued?

Graham number

The Graham number of Scynexis Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scynexis Inc fundamental analysis

No fundamental analysis for Scynexis Inc yet.

Scynexis Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scynexis Inc

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS…

Full company profile